Roxadustat as a Hypoxia-Mimetic Agent: Erythropoietic Mechanisms, Bioanalytical Detection, and Regulatory Considerations in Sports Medicine

Roxadustat (ROX) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PHI) that exerts erythropoietic, cardioprotective, and metabolic regulatory effects. Approved for the treatment of anemia associated with chronic kidney disease, ROX promotes endogenous erythropoietin...

Full description

Bibliographic Details
Published in:	Current Issues in Molecular Biology
Main Authors:	Elena-Christen Creangă, Cristina Ott, Alina-Crenguţa Nicolae, Cristina Manuela Drăgoi, Raluca Stan
Format:	Article
Language:	English
Published:	MDPI AG 2025-09-01
Subjects:	roxadustat erythropoietin chronic kidney disease hypoxia-inducible factor prolyl hydroxylase inhibitor bioanalysis Quechers method
Online Access:	https://www.mdpi.com/1467-3045/47/9/734

Similar Items

Issues on clinical application of hypoxia-inducible factor prolyl hydroxylase inhibitor Roxadustat
by: TU Yan, et al.
Published: (2020-01-01)

A Case Report of Hypothyrotropin Hypothyroidism Caused by Roxadustat
by: YAN Xuelian, et al.
Published: (2025-03-01)

Roxadustat for ESA‐Hyporesponsive Renal Anemia in a 13‐Year‐Old on Hemodialysis: Case Report and Mini‐Review
by: Meng Zhang, et al.
Published: (2025-10-01)

Research progress on roxadustat treatment for renal anemia
by: HU Bao-li, HU Bin
Published: (2022-09-01)

Randomized Study on the Efficacy of Standard Versus Low Roxadustat Dose for Anemia in Patients on Peritoneal Dialysis
by: Zhikai Yang, et al.
Published: (2022-03-01)

Case report: Roxadustat overdose in an anemia patient of chronic kidney disease: insight beyond insignificant consequence
by: Long-Guang Zhang, et al.
Published: (2024-08-01)

The Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease
by: Ryujiro Hara, et al.
Published: (2021-11-01)

Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study
by: Emiko Otsuka, et al.
Published: (2024-12-01)

Low cholesterol levels are good markers for central hypothyroidism in case with dialysis using roxadustat
by: Serina Kita, et al.
Published: (2024-09-01)

Roxadustat for the Treatment of Early Post-Transplantation Anemia
by: Louis Guenal, et al.
Published: (2025-10-01)

Thyroid function analysis after roxadustat or erythropoietin treatment in patients with renal anemia: a cohort study
by: Xiaomeng Zheng, et al.
Published: (2023-12-01)

Roxadustat: Do we know all the answers?
by: Qiu-Yu Li, et al.
Published: (2023-05-01)

Effects of Roxadustat on Erythropoietin Production in the Rat Body
by: Yukiko Yasuoka, et al.
Published: (2022-02-01)

Roxadustat in CKD and transplant patients: A new era in anemia management
by: Muhammad Tassaduq Khan, et al.
Published: (2025-03-01)

Dysfunction of von-Hippel Lindau factor causes reduced degradation of HIF leading to renal cancer. Hypoxia-inducible factor-prolyl hydroxylase enzyme inhibitors also lessen HIF destruction and could therefore increase renal cancer
by: Helge Waldum
Published: (2023-06-01)

Effectiveness and Safety of Roxadustat for Renal Anemia in Dialysis-dependent Chronic Kidney Disease: a Meta-analysis
by: LI Jiaqing, YANG Qing, YUAN Dunlu, HUANG Jingjing, CHANG Qing, NIE Jingwen, ZHOU Zhu, LI Qing
Published: (2023-02-01)

Treatment of anemia of chronic kidney disease caused by ANCA associated vasculitis with roxadustat:one case report with a literature review
by: Xiao Xiang, et al.
Published: (2021-01-01)

Assessment of the safety of Roxadustat for cardiovascular events in chronic kidney disease-related anemia using meta-analysis and bioinformatics
by: Xiangmeng Li, et al.
Published: (2024-06-01)

The HIFα-Stabilizing Drug Roxadustat Increases the Number of Renal Epo-Producing Sca-1<sup>+</sup> Cells
by: Aline Jatho, et al.
Published: (2022-02-01)

UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease
by: Sunil Bhandari, et al.
Published: (2025-04-01)

Hypertension Induced by Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors in Treating Anemia in Patients With Chronic Kidney Disease: A Mini‐Review
by: Wei Zhang, et al.
Published: (2024-12-01)

Comparison between the influence of roxadustat and recombinant human erythropoietin treatment on blood pressure and cardio-cerebrovascular complications in patients undergoing peritoneal dialysis
by: Shuiqin Cheng, et al.
Published: (2023-06-01)

Influencing factors of clinical efficacy of roxadustat among hemodialysis patients
by: Wenhui Wu, et al.
Published: (2024-12-01)

Clinical efficacy and safety analysis in initial hemodialysis patient with renal anemia treated by roxadustat or recombinant human erythropoietin
by: Zhang Peng-jie, et al.
Published: (2022-11-01)

Effects of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, on sodium dynamics in hypertensive subtotally nephrectomized rats
by: Anqi Zhang, et al.
Published: (2021-06-01)

Study on HIF-PHI combined with iron supplement in treatment of renal anemia in rats
by: Zhaoli Gao, et al.
Published: (2025-03-01)

Stabilizing Hypoxia-Inducible Factor to Manage Anemia in Chronic Kidney Disease: From Basic Theory to Clinical Study
by: Yudian Wang, et al.
Published: (2024-01-01)

Roxadustat Attenuates Adverse Remodeling Following Myocardial Infarction in Mice
by: Marc-Michael Zaruba, et al.
Published: (2024-06-01)

Neuroprotective Effect of HIF Prolyl Hydroxylase Inhibition in an In Vitro Hypoxia Model
by: Maria Savyuk, et al.
Published: (2020-07-01)

The role and clinical implications of HIF-PHI daprodustat in dialysis-dependent and non-dialysis-dependent chronic kidney disease anemic patients: a general review
by: Yousuf Abdulkarim Waheed, et al.
Published: (2024-12-01)

Roxadustat reduced the risk of perioperative complication arising from the treatment of cardiac paraganglioma: A case report
by: Dong Wang, et al.
Published: (2023-09-01)

Roxadustat: Not just for anemia
by: Xiaoyu Zhu, et al.
Published: (2022-08-01)

Roxadustat on Renal Anemia with Macroinflammation: A Retrospective Cohort Study
by: Yan Tu, et al.
Published: (2024-03-01)

Plasma phospholipids profiling changes were associated with the therapeutic response to Roxadustat in peritoneal dialysis patients
by: Ya-Hui Yang, et al.
Published: (2023-12-01)

Roxadustat for Patients with Posttransplant Anemia: A Narrative Review
by: Xiaoxiao Tang, et al.
Published: (2023-11-01)

Effect of roxadustat on iron metabolism in patients with peritoneal dialysis: a real-world 24-week study
by: Xuejie Zhang, et al.
Published: (2023-11-01)

A Pharmacodynamic Evaluation of the Protective Effects of Roxadustat Against Hypoxic Injury at High Altitude
by: Guo Q, et al.
Published: (2023-01-01)

Roxadustat for the treatment of anemia in patients with chronic kidney disease: a Meta-analysis
by: WANG Rui, et al.
Published: (2019-01-01)

A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness
by: Jie Liu, et al.
Published: (2024-05-01)

Diabetic Cardiomyopathy and Prolyl Hydroxylases
by: Fırat Akat, et al.
Published: (2017-04-01)